Emerging pharmaceutical therapies for COPD

COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediator...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakshmi, Sowmya P, Reddy, Aravind T, Reddy, Raju C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/
https://www.ncbi.nlm.nih.gov/pubmed/28790817
http://dx.doi.org/10.2147/COPD.S121416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/
https://www.ncbi.nlm.nih.gov/pubmed/28790817
http://dx.doi.org/10.2147/COPD.S121416

Ejemplares similares